TEM

Business Context and Reporting Period

Tempus AI, Inc. (Tempus) is a healthcare technology company focused on applying artificial intelligence and machine learning to improve patient care through genomic testing, data licensing, and clinical trial matching. This Form 10-Q covers the quarterly period ended June 30, 2024. A significant corporate event during this period was the company's Initial Public Offering (IPO), completed on June 17, 2024, which resulted in the conversion of all outstanding redeemable convertible preferred stock into common stock.

Key Financial Metrics

Note: The filing text does not provide a clear value for gross margin percentages; however, Cost of Revenues for the three months ended June 30, 2024, was $90.46 million.

Material Changes vs. Prior Period

• Revenue Growth: Total net revenue increased 25% year-over-year for the three months ended June 30, 2024, driven by a 22% increase in Genomics revenue and a 32% increase in Data and Services revenue.
• Expense Surge: Selling, General, and Administrative (SG&A) expenses increased 550% year-over-year to $463.07 million. This was primarily due to a one-time recognition of $488.3 million in stock-based compensation expense triggered by the satisfaction of liquidity event vesting conditions upon the IPO.
• Operating Loss: Loss from operations widened significantly to $(533.49) million for the quarter, compared to $(45.14) million in the prior year period, largely attributable to the non-cash stock-based compensation charge.
• Liquidity: Cash and cash equivalents increased from $165.77 million at December 31, 2023, to $478.81 million at June 30, 2024, following the IPO which generated net proceeds of $382.0 million and a Series G-5 preferred stock financing of $200.0 million.

Guidance, Outlook, and Risks

• Outlook: Management expects to continue incurring operating losses as it invests in product innovation, sales expansion, and technology development. The company believes its current cash position is sufficient to fund operations for more than twelve months.
• Debt Covenants: The company is subject to revenue covenants under its Term Loan Facility, requiring consolidated revenues of $459.1 million for the year ended December 31, 2024, and $594.1 million for 2025.
• Legal Proceedings: On June 11, 2024, Guardant Health filed a patent infringement complaint alleging Tempus products infringe five U.S. patents. Additionally, the company is responding to a Civil Investigative Demand from the U.S. Attorney's Office regarding compliance with the False Claims Act and Anti-Kickback statutes.
• Subsequent Events: In July 2024, Tempus closed a Joint Venture with SoftBank Group Corporation in Japan, capitalizing the entity with approximately $191.1 million.
• Stock-Based Compensation: Future tax withholding obligations related to the settlement of Restricted Stock Units (RSUs) vested in connection with the IPO may require significant cash outlays or sell-to-cover transactions, which could impact the stock price.

Investor Verification Checklist

• Revenue Quality: Verify the sustainability of revenue growth excluding the impact of one-time revenue reserve releases ($1.2 million in Q2 2024).
• Debt Service: Confirm the company's ability to meet the $459.1 million revenue covenant for the full year 2024 given the current run rate.
• Legal Exposure: Monitor the status of the Guardant Health patent litigation and the government investigation regarding billing practices.
• Non-GAAP Reconciliation: Review the reconciliation of Adjusted EBITDA to Net Loss to understand the magnitude of non-cash charges (specifically the $488.3 million stock-based compensation) relative to core operations.
• Reimbursement Rates: Assess the impact of changing Medicare reimbursement policies and CPT coding on the Genomics segment, which represents the majority of revenue.